Compugen (CGEN) CEO Ophir Eran Receives 200,000-Share Award

What Happened
Ophir Eran, President, CEO and Director of Compugen Ltd (CGEN), was granted a derivative award representing 200,000 shares on July 29, 2026. The award shows an acquisition price of $0.00 (no cash paid at grant) and is reported as a derivative grant rather than an open-market purchase or sale. This is a compensation award rather than an immediate purchase or sale of tradable shares.

Key Details

• Transaction date: July 29, 2026; filing date: July 30, 2026. No late filing is indicated in the provided data.
• Award size: 200,000 shares; reported acquisition price: $0.00 (derivative grant, $0 immediate cash value reported).
• Vesting (footnote F1): 25% vests on September 30, 2027; remaining 75% vests in 12 equal quarterly installments thereafter, subject to continued service.
• Shares owned after transaction: not specified in the excerpt of the filing.
• No indication of a 10b5-1 plan, tax-withholding sale, or immediate sale of shares — this was a grant, not a sale/exercise.

Context
This grant is a common form of executive compensation (options or RSU-style derivative award). Because it vests over time and was granted at $0.00, it does not represent an immediate cash investment or proceeds and does not imply immediate buying or selling of market-listed shares. Derivative awards typically convert into actual shares only after vesting (and possibly exercise), so any future market impact depends on vesting, exercise, and subsequent sales.